4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide

We are 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide CAS:284462-37-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide
CAS.NO:  284462-37-9
Synonyms:
THIOPHENE 2-CARBONITRILE
4-(4-Aminophenoxy)-N-methylpicolinamide
4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamide
4-[(4-aminomethyl)phenoxy]-2-pyridine carbonic acid methylamide
4-[(4-aminophenoxy)(2-pyridyl)]-N-methylcarboxamide
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline
4-(4-amino-phenoxy)-pyridine-2-carboxylic acid methylamide

Molecular Formula: C13H13N3O2
Molecular Weight:   243.26100

Physical and Chemical Properties:
Density: 1.241 g / cm3
Boiling point: 476.8ºC at 760 mmHg
Melting point: 110-112ºC
Flash point: 242.2ºC
Refractive index: 1.618

Specification:
Appearance:  White powder
Purity:≥98.0%
water content:≤0.2%
Residue on Ignition:0.05%
Related Substance:0.26%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Sorafenib tosylate CAS:475207-59-1.

Related News: The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion.2-N-ciclopropilamino-4,6-dicloro-triazina CAS:32889-45-5 From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.N,N-Diethyl-3-(trimethoxysilyl)propan-1-amine CAS:41051-80-3 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”4-Chloro-3-nitroanisole CAS:10298-80-3 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.